Overview * Biogen Q3 2025 revenue of $2.5 bln beats analyst expectations * Adjusted EPS of $4.81 for Q3 2025 beats consensus estimates * Company updates full-year 2025 guidance, projecting slight revenue increase Outlook * Biogen expects 2025 Non-GAAP EPS between $14.50 and $15.00 * Company anticipates 2025 revenue to be flat to up 1% vs 2024 * Biogen foresees increased competitive pressures on ex-U.S. MS business Result Drivers * LAUNCH PRODUCTS – 67% year-over-year growth in Alzheimer's, rare disease, and postpartum depression products drove revenue increase * LEQEMBI SALES – LEQEMBI global sales grew 82% year-over-year, with steady growth in the U.S. and demand growth ex-U.S. * MS FRANCHISE – MS franchise grew 1% year-over-year, aided by favorable adjustments and strong demand for VUMERITY in the U.S. Key Details Metric Beat/Mis Actual Consensu s s Estimate Q3 Beat $2.50 $2.33 Revenue bln bln (26 Analysts ) Q3 Beat $4.81 $3.88 Adjusted (26 EPS Analysts ) Q3 EPS $3.17 Analyst Coverage * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 20 "hold" and no "sell" or "strong sell" * The average consensus recommendation for the pharmaceuticals peer group is "buy" * Wall Street's median 12-month price target for Biogen Inc is $160.00, about 7.6% above its October 29 closing price of $147.86 * The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 8 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
